At Selecta Biosciences, our vision is to profoundly impact the lives of patients by seeking to become the first biopharmaceutical company to develop and commercialize differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases.
Our SVP products are designed to induce antigen-specific immune tolerance to mitigate the formation of ADAs in response to life-sustaining biologic drugs and also have the potential to be used for therapies that stimulate the immune system to prevent and treat cancer, infections and other diseases. Our SVP technology is a highly flexible nanoparticle platform, allowing us to tailor our SVP products for specific applications across multiple indications.
I am thrilled to be part of our talented and dedicated team both in Boston and Moscow. I am proud of the results we have achieved – and we will continue to make progress toward our strategic vision. We recognize and value the importance of our team members and we seek to recruit those who share our passion and are inspired by the potential of our technology to make a difference for patients. We invite you to learn more about Selecta Biosciences, our people, our technology, and the many possibilities for collaborations.
Werner Cautreels, Ph.D.
President and CEO
Selecta Biosciences, Inc.